|
Introduction
The pharmaceutical industry plays a vital role in ensuring public health by developing, manufacturing, and distributing medicines and medical devices. However, the relationship between pharmaceutical companies and healthcare professionals has long been scrutinised due to unethical marketing practices. For many years, reports surfaced of pharmaceutical companies offering gifts, expensive travel, hospitality, and financial incentives to doctors in exchange for prescribing their products. Such practices not only undermined medical ethics but also increased healthcare costs and compromised patient welfare.
To address these concerns, the Government of India introduced the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) in 2015. However, as the code was voluntary, compliance remained inconsistent and ineffective. Recognising the need for a stronger regulatory framework, the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilisers, notified the UCPMP 2024, making ethical marketing standards mandatory for pharmaceutical companies. The code came into force on 12 April 2024 and was further streamlined through revisions in September 2025. In July 2026, the Government reaffirmed its commitment to the framework through a parliamentary disclosure in the Lok Sabha.
Evolution from a Voluntary Code to a Mandatory Framework
The original UCPMP was notified on 12 December 2014 and became operational on 1 January 2015. It encouraged pharmaceutical companies to adopt ethical marketing practices voluntarily. Since there were no enforceable penalties or monitoring mechanisms, many companies failed to comply effectively.
To overcome these shortcomings, the Government issued UCPMP 2024 on 12 March 2024, making compliance compulsory for all pharmaceutical companies operating in India. The code became effective from 12 April 2024, replacing the earlier voluntary framework. In September 2025, the Government introduced procedural revisions to simplify compliance while maintaining transparency. The deadline for filing annual compliance declarations and marketing expenditure disclosures was extended to 30 September 2025, reducing administrative burdens without diluting ethical standards.
On 24 July 2026, Minister of State for Chemicals and Fertilizers Anupriya Patel informed the Lok Sabha about the implementation and major provisions of the code, reaffirming the Government's commitment to ethical pharmaceutical marketing.
Major Provisions of UCPMP 2024
1. Establishment of Ethics Committees
The code mandates the establishment of Ethics Committees for Pharmaceutical Marketing Practices (ECPMP) at the level of pharmaceutical industry associations. These committees monitor compliance, examine complaints, and ensure that companies adhere to ethical marketing standards.
2. Appointment of Ethics Officers
Every pharmaceutical company must appoint a designated Ethics Officer responsible for implementing the code within the organisation. The officer serves as the primary compliance authority and ensures that all promotional activities conform to legal and ethical requirements.
3. Complaint Redressal and Appeal Mechanism
A structured two-tier grievance redressal system has been introduced:
This mechanism provides transparency, accountability, and an accessible forum for addressing violations.
4. Mandatory Self-Declaration
Every pharmaceutical company must submit a self-declaration confirming compliance with the provisions of the code. The declaration reinforces corporate accountability by requiring companies to certify that their promotional activities are ethical and lawful.
5. Annual Disclosure of Marketing Expenditure
The revised code requires companies to file annual statements detailing their promotional and marketing expenditure. These disclosures are intended to be publicly available, promoting greater transparency and enabling regulatory oversight.
6. Prohibition on Gifts and Hospitality
One of the most significant provisions of UCPMP 2024 is the absolute prohibition on offering gifts, cash, hospitality, travel facilities, entertainment, or other monetary benefits to doctors and their family members. This seeks to eliminate conflicts of interest and ensure that medical prescriptions are based solely on scientific evidence and patient welfare rather than commercial incentives.
7. Accountability for Employee Conduct
The code places responsibility on pharmaceutical companies for the actions of their medical representatives and employees. Companies cannot evade liability by attributing unethical conduct to individual employees, thereby encouraging stronger internal compliance systems.
8. Regulation of Medical Representatives
Medical representatives are required to promote medicines responsibly and provide accurate, balanced, and evidence-based information to healthcare professionals. Misleading claims, exaggerated promotional material, or unethical inducements are strictly prohibited.
9. Transparency in Educational Events
Companies often sponsor Continuing Medical Education (CME), Continuing Professional Development (CPD) programmes, conferences, and seminars. Under UCPMP 2024, all expenses incurred on such educational activities must be publicly disclosed to prevent academic events from becoming indirect channels for influencing doctors.
10. Audit and Monitoring
The code permits independent, random, and risk-based audits to verify compliance. Such audits strengthen regulatory oversight and encourage companies to maintain accurate records and transparent practices.
11. Broad Scope of Application
Unlike earlier regulatory approaches that primarily focused on medicines, UCPMP 2024 expressly applies to both pharmaceutical products and medical devices. It covers all entities engaged in manufacturing, marketing, distribution, and sale, thereby expanding its regulatory reach across the healthcare sector.
Legal Significance
The transition from a voluntary code to a mandatory compliance framework marks a major development in India's pharmaceutical regulatory regime. By making ethical marketing legally enforceable, the Government has shifted from encouraging good practices to mandating accountability.
The code also complements the ethical regulations applicable to medical practitioners under the National Medical Commission (NMC). While the NMC restricts doctors from accepting gifts or financial benefits from pharmaceutical companies, UCPMP 2024 regulates the conduct of the companies themselves. Together, these frameworks address both sides of unethical transactions and strengthen professional integrity.
Additionally, the legal framework is reinforced through tax policy. Pharmaceutical companies are not permitted to claim income tax deductions for gifts, incentives, or prohibited promotional expenditure provided to doctors. This removes the financial advantage associated with unethical marketing practices.
The Supreme Court of India has also examined issues relating to unethical pharmaceutical marketing in various proceedings and has emphasised the need for greater transparency. During these proceedings, the Court has referred to the objectives of UCPMP 2024 in curbing inducements such as gifts, travel, and hospitality offered to healthcare professionals.
Challenges and the Way Forward
Although UCPMP 2024 represents a significant reform, effective implementation remains crucial. Success will depend upon regular audits, prompt disposal of complaints, strict enforcement by Ethics Committees, and active monitoring by the Department of Pharmaceuticals. Continuous awareness programmes for pharmaceutical companies, healthcare professionals, and medical representatives will also be essential to foster a culture of ethical compliance.
The effectiveness of the framework will ultimately depend on whether regulatory authorities consistently enforce the provisions and impose appropriate consequences for violations.
Conclusion
The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 marks a landmark reform in India's healthcare regulatory framework. By making ethical marketing standards mandatory, prohibiting gifts and financial inducements to doctors, requiring transparency in promotional expenditure, establishing ethics committees, and introducing structured complaint mechanisms, the Government has taken a decisive step towards improving accountability within the pharmaceutical industry.
These reforms promote ethical medical practice, protect patient interests, enhance public confidence in healthcare, and encourage fair competition among pharmaceutical companies. As the code continues to evolve through regulatory oversight and judicial scrutiny, it has the potential to become one of the most significant governance reforms in India's pharmaceutical sector, ensuring that healthcare decisions remain guided by patient welfare rather than commercial influence.
Reference
Tags : International Legal Article
Copyright A unit of White Code Global Consulting Pvt Ltd. All rights reserved. Unless otherwise indicated, all materials on these pages are copyrighted by A unit of White Code Global Consulting Pvt Ltd. All rights reserved. No part of these pages, either text or image may be used for any purpose. By continuing past this page, you agree to our Terms of Service, Cookie Policy, Privacy Policy and Content Policies.
